 |
51 Diseases |  |
15 Trials |
|
15 Trials |  |
1554 News |  |
| «12345678910111213...1718» |
- Imcivree (setmelanotide) / Rhythm Pharma
Advantages of genetic testing in the evaluation of pediatric obesity () - Mar 14, 2023 - Abstract #PAS2023PAS_2177;
Genetic testing revealed heterozygosity for two MC4R gene variants. The hypothalamic melanocortin 4 receptor (MC4R) pathway regulates weight by influencing hunger, satiety, metabolic rate and energy balance.
- carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Lamotrigine as a First-line Agent in the Management of Paroxysmal Kinesigenic Dyskinesia (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4293;
Conclusions Lamotrigine is an effective first line alternative to carbamazepine and oxcarbazepine for PKD. It is a safer choice for females of child bearing potential and may have increased tolerability.
- gabapentin / Generic mfg., oxcarbazepine / Generic mfg.
Multiple Sclerosis Related Trigeminal Neuralgia (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3868;
It is a safer choice for females of child bearing potential and may have increased tolerability. Conclusions MS patients with TN experienced neurogenic pain of multiple types and high severity.
- oxcarbazepine / Generic mfg.
Autosomal Dominant Trigeminal Neuralgia (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2768;
His symptoms were well-controlled on oxcarbazepine...There are few case reports of familial trigeminal neuralgia, and this case has a particularly high number of family members affected. Physicians should be aware that trigeminal neuralgia can rarely be a familial disorder, and should consider family history when evaluating patients for trigeminal neuralgia.
- oxcarbazepine / Generic mfg.
Neurogenetics: Congenital Myotonic Dystrophy with asymptomatic mother may be missed by whole exome sequencing; Biopsy, DMPK1 gene testing and EMG may be required to resolve VUS in neonates, A Case report. (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2552;
A week after tracheostomy and g-tube placement, oxcarbazepine was trialed, after which he was able to be weaned off ventilation and discharged to home...Myotonia may be found in neonates as young as 6 days old characterized as briefer duration with waning repetitive small amplitudes between 50-100uV without the classic sound on a spectrum with complex repetitive discharges. Severe congenital myotonic dystrophy patients may be born from an asymptomatic mother and the diagnosis may be missed by whole exome sequencing.
- Deep Brain Stimulation in Hemimegalencephaly with Medically Intractable Epilepsy: A Case Report (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2093;
Given the absence of motor deficits, hemispherectomy was not considered. This is a novel case of DBS being utilized in the management of hemimegalencephaly.
- PRAX-562 / Praxis Precision Medicines
PRAX-562-102: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1988;
Most AEs including SAEs in Part B were considered due to coadministration of projected supratherapeutic doses of PRAX-562 with OXC. Our PK and tolerability findings are consistent with a wide therapeutic window for PRAX-562, while PD findings indicate qEEG may be a sensitive translational biomarker of sodium channel blockade.
- vigabatrin / Generic mfg.
Efficacy of Vigabatrin as Treatment for Seizures in Children Without Infantile Spasms (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1986;
In one case, one child developed encephalopathy in combination with CBD. Otherwise, vigabatrin has been safe over the long term.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
The Pharmacokinetics of Cenobamate When Used as Monotherapy (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1890;
Therefore, plasma cenobamate exposures with adjunctive therapy were comparable to monotherapy. Conclusions Based on these findings, cenobamate monotherapy should result in plasma exposures comparable to those that have been demonstrated to be safe and effective when used as adjunctive therapy for the treatment of focal seizures.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Concomitant Antiseizure Medication Dose Reduction and Discontinuation After Starting Cenobamate: a Retrospective Review (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1885;
Seizure control was maintained or improved during treatment. These data suggest that cenobamate therapy may allow a reduction or elimination of polytherapy in some patients.
- | Journal, Monotherapy: Comparative safety of antiseizure medication monotherapy for major malformations. (Pubmed Central) - Mar 2, 2023
Conversely, we found no increased risks for lamotrigine, carbamazepine, oxcarbazepine, or levetiracetam, which is reassuring. ANN NEUROL 2023;93:551-562.
- | oxcarbazepine / Generic mfg.
Journal: Theoretical insights into the degradation mechanisms, kinetics and eco-toxicity of oxcarbazepine initiated by OH radicals in aqueous environments. (Pubmed Central) - Feb 27, 2023
Conversely, green algae are more sensitive to these compounds. This study can provide an extensive investigation into the degradation of OXC by OH radicals and enrich the understanding of the aquatic oxidation processes of pharmaceuticals and personal care products (PPCPs).
- | phenytoin / Generic mfg., clobazam / Generic mfg., oxcarbazepine / Generic mfg.
New P4 trial: The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children (clinicaltrials.gov) - Jan 26, 2023
P4, N=100, Recruiting, Sponsor: Dr Cipto Mangunkusumo General Hospital
- | carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Expanding the phenotypic spectrum of KCNK4: From syndromic neurodevelopmental disorder to rolandic epilepsy. (Pubmed Central) - Jan 24, 2023
Phenotypic variations of KCNK4 are potentially associated with the molecular sub-regional effects. Carbamazepine/oxcarbazepine and valproate may be effective antiepileptic drugs for patients with KCNK4 variants.
- | Journal: Trends in antiseizure medications utilization among women of childbearing age with epilepsy in Poland between 2015 and 2019. (Pubmed Central) - Jan 23, 2023
Valproate is still the most commonly prescribed ASM in WOCA and girls aged 12-14 years. Educational interventions for healthcare professionals are needed to improve prescribing practices in WOCA with epilepsy in Poland.
- | oxcarbazepine / Generic mfg.
Journal: Effect of Penetration Enhancers on Transdermal Delivery of Oxcarbazepine, an Antiepileptic Drug Using Microemulsions. (Pubmed Central) - Jan 22, 2023
The flux of drug delivery from the various formulations was found to be, in decreasing order, cin > OA + TRC > NMP > TRC > OA. Overall, microemulsions prepared using cineole, Tween 80 and Transcutol P (TRC) were shown to be provide the best penetration enhancement for OXC.
- | Journal: PACS gene family-related neurological diseases: limited genotypes and diverse phenotypes. (Pubmed Central) - Jan 17, 2023
These findings may provide an important clue for further functional studies on the pathogenic mechanism of neurological disorders related to the PACS gene family. Video Abstract (MP4 65767 kb).
- | Journal: Features of the choice and the use of antiepileptic drugs as analgesics in elderly. (Pubmed Central) - Jan 9, 2023
Variety of antiepileptics used as analgesics have variable efficacy and safety profile in elderly. «Old» antiepileptics (phenobarbital, clonazepam, ethosuximide, carbamazepine, phenytoin, valproate, etc.) and «new» (gabapentin, pregabalin, oxcarbazepine, lamotrigine, levetiracetam, topiramate, zonisamide, tiagabine) are considered in this review with insights on pharmacokinetic features of these drugs in elderly, profile of side effects, parameters of analgesic efficacy.
- | oxcarbazepine / Generic mfg.
Journal: Effect of Oxcarbazepine on Language Function in Patients With Newly Diagnosed Pediatric Epilepsy. (Pubmed Central) - Jan 7, 2023
«Old» antiepileptics (phenobarbital, clonazepam, ethosuximide, carbamazepine, phenytoin, valproate, etc.) and «new» (gabapentin, pregabalin, oxcarbazepine, lamotrigine, levetiracetam, topiramate, zonisamide, tiagabine) are considered in this review with insights on pharmacokinetic features of these drugs in elderly, profile of side effects, parameters of analgesic efficacy. Our results suggest that OXC is safe and preserves language function in patients with pediatric epilepsy.
- oxcarbazepine / Generic mfg.
MULTIFACTORIAL BRUGADA SYNDROME WITH HISTORY OF SEIZURES (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_46;
Several BrS inducers are present in this case, including both seizures and antiepileptic medications, but fever is a more common precipitant. Consideration of all modulating factors is critical to BrS management.
- || Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Retrospective data, Review: Comparative antiseizure medications of adjunctive treatment for children with drug-resistant focal-onset seizures: A systematic review and network meta-analysis. (Pubmed Central) - Jan 3, 2023
According to the surface under the cumulative ranking curve ranking, lamotrigine, levetiracetam, and oxcarbazepine were more efficacious than other active antiseizure medications in terms of responder rate. Concerning tolerability, oxcarbazepine was more likely to lead to dropout and topiramate was associated with higher occurrence of side effects.
- | Journal: Zebrafish EEG predicts the efficacy of antiepileptic drugs. (Pubmed Central) - Dec 27, 2022
Moreover, the 50% effective doses (ED50) of valproate acid and tiagabine were determined based on zebrafish EEG for the first time, indicating that the quantitative inter-species comparison of the AED efficacy is possible between zebrafish and mammals such as rodents. Significance: The results show that zebrafish can be used to effectively and quantitatively evaluate the efficacy of AEDs based on EEG, the same method to evaluate antiepileptic effects in mammals, suggesting that the proposed method can contribute in reducing the cost and duration of search for AEDs and thus accelerate the drug development cycles.
- | phenobarbital / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Clinical Characteristics of Seizures and Epilepsy in Individuals With Recurrent Deletions and Duplications in the 16p11.2 Region. (Pubmed Central) - Dec 20, 2022
Seizures responded favorably to phenobarbital, carbamazepine, and oxcarbazepine in the deletion group, specifically in the Se(F)IE, and to various antiseizure medications in the duplication group. These findings delineate the spectrum of seizures and epilepsies in the recurrent 16p11.2 deletions and duplications and provide potential diagnostic, therapeutic, and prognostic information.
- | Journal: Cytochrome P450-mediated antiseizure medication interactions influence apoptosis, modulate the brain BAX/Bcl-X ratio and aggravate mitochondrial stressors in human pharmacoresistant epilepsy. (Pubmed Central) - Dec 16, 2022
We divided the patients into groups-those who took combinations of NON-CYP + CYP substrate ASMs, NON-CYP + CYP inducer ASMs, CYP substrate + CYP substrate or CYP substrate + CYP inducer ASMs-to study the 1) pro- and anti-apoptotic protein levels and other apoptotic signaling proteins and levels of reactive oxygen species (reduced glutathione and lipid peroxidation) in brain tissues; 2) cytotoxicity at blood-brain barrier epileptic endothelial cells (EPI-ECs) and subsequent changes in mitochondrial membrane potential in normal neuronal cells, following treatment with LCM + OXC (CYP substrate + CYP inducer) or LCM + LEV (CYP substrate + NON-CYP-substrate) after blood-brain barrier penetration, and 3) apoptotic and mitochondrial protein targets in the cells, pre-and post-CYP3A4 inhibition by ketoconazole and drug treatments...Together, the study highlights for the first time that pro- and anti-apoptotic proteins levels are dependent on ASM combinations in epilepsy, modulated via a CYP-mediated mechanism that controls free radicals, cytotoxicity and mitochondrial activity. These findings lead to a better understanding of future drug selection choices offsetting pharmacodynamic CYP-mediated interactions.
- || phenytoin / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Journal, Adverse drug reaction: Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions. (Pubmed Central) - Dec 9, 2022
Use of HLA-B genotyping may aid clinicians in the diagnosis of carbamazepine, phenytoin, lamotrigine and oxcarbazepine induced SJS/TEN, particularly in Han Chinese and Southeast Asian patients. On the other hand, patch tests seem to perform better in the diagnosis of carbamazepine and phenytoin induced DRESS.
- | lithium carbonate ER / Generic mfg.
Journal: Psychopharmacological Treatment Algorithms of Manic/Mixed and Depressed Episodes in Pediatric Bipolar Disorder. (Pubmed Central) - Dec 7, 2022
We offer an update to the 2005 AACAP algorithms for the treatment of pediatric bipolar mixed/manic episodes and added an evidence-based algorithm for the treatment of depression in PBD. In addition to treatment algorithms, we review current evidence for efficacy of agents proposed in the AACAP algorithm and provide tables summarizing medication side effects and efficacy.
- | oxcarbazepine / Generic mfg.
Journal: Sex differences in variables associated with excessive daytime sleepiness in patients with epilepsy. (Pubmed Central) - Dec 7, 2022
In addition to treatment algorithms, we review current evidence for efficacy of agents proposed in the AACAP algorithm and provide tables summarizing medication side effects and efficacy. Sex is likely to be a key factor in determining contributors to EDS in PWE.
- | sodium valproate / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Clinical characteristics and genetics of ten Chinese children with PRRT2-associated neurological diseases. (Pubmed Central) - Dec 6, 2022
This mutation site is highly conserved in most species, and there was no significant correlation between specific PRRT2 genotypes and clinical phenotypes. Asymptomatic carriers also have decreased gene expression levels, suggesting that more factors are involved.
- | levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Retrospective data, Journal: Effects of new antiseizure medication on bone metabolism and bone mineral density in children: A meta-analysis. (Pubmed Central) - Dec 3, 2022
However, the effects of new antiseizure medication on serum calcium and bone alkaline phosphatase in children were not statistically significant. New antiseizure medication have different effects on bone metabolism and bone mineral density in children with epilepsy, and the effects of different types of new antiseizure medication are different.
- | Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Journal: Paxlovid Information From FDA and Guidance for AES Members. (Pubmed Central) - Dec 2, 2022
ASMs that are metabolized, at least in part, by CYP3A4 include cannabidiol, carbamazepine, clobazam, clonazepam, diazepam, ethosuximide, everolimus, felbamate, lacosamide, midazolam, oxcarbazepine, perampanel, stiripentol, tiagabine, and zonisamide. Patients receiving these medications may warrant closer monitoring while being treated with Paxlovid.
- | carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy. (Pubmed Central) - Nov 29, 2022
After failing the first ASM, two-thirds of the patients responded to subsequent ASM regimens. Our results support the feasibility and applicability of the ILAE concept of an adequate ASM trial and the failure of two ASMs as a definition of DRE.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Dose Reduction and Discontinuation of Concomitant Antiseizure Medications After Initiating Cenobamate: Results from a Retrospective Review (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1906;
Seizure control was maintained or improved during cenobamate treatment. These data suggest that cenobamate therapy may allow a reduction or elimination of polytherapy in some patients.
- Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Association Between Acute Care Utilization and First Drug Choice in Adults with Newly Diagnosed Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1901;
Adults with newly diagnosed epilepsy are frequent users of acute care. Initial multivariable model suggests that comorbid disease, including neurologic comorbidity, benzodiazepine prescription and ASM polypharmacy may be drivers of acute care use in this population.
- Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Human Epilepsy Project 2 (HEP2): Lifetime and Current ASM Profile for Patients with Refractory Epilepsy () - Nov 29, 2022 - Abstract #AES2022AES_1637;
While levetiracetam demonstrated the highest lifetime use (92.5% of subjects), only 38% subjects reported use at baseline. Phenytoin demonstrated the lowest rate of continuation at 10.8%.
- Clinical presentation and treatment of epilepsy in cardiofaciocutaneous syndrome: an observational cohort study () - Nov 29, 2022 - Abstract #AES2022AES_1636;
Although other ASMs were prescribed more frequently, oxcarbazepine had highest efficacy in moderating seizures and less frequent adverse effects. Limitations include a lack of comprehensive information about dosing regimens and drug trial duration, along with reliance on retrospectively reported survey data.
- An Online Survey of Caregivers of Patients with KCNQ2 Developmental and Epileptic Encephalopathy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1600;
Moreover, caregivers described dissatisfaction with current treatment options. There is a significant unmet medical need that requires better treatments for KCNQ2-DEE.
- oxcarbazepine / Generic mfg.
SCN1A Philadelphia Variant – a Recurrent Gain-of-function Variant Causing an Early-onset Epileptic Encephalopathy Distinct from Dravet Syndrome (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1493;
Functional consequences of this variant include a mixed gain and loss of channel function albeit with normal current density and prominent impairment of fast inactivation with increased persistent Na+ current. Na+ channel blockers did not fully correct the identified electrophysiological abnormalities in vitro, but may offer some therapeutic clinical benefit with early administration.
- Variations in Prescribing Practices for Early Life Epilepsy, a Pediatric Epilepsy Learning Healthcare System Study (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1391;
Drivers may include age, physician preference (center-to-center variations), ability to pay (insurance status), and race/ethnicity. Additional work is necessary to incorporate clinical drivers of ASM selection into our models (i.e., seizure type and burden, epilepsy etiology, and comorbidity profile).
- carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Implications of an Early Diagnosis of Dravet Syndrome - The Role of a Developmental and Epileptic Encephalopathy Nurse (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1365;
Therefore, earlier diagnosis informed appropriate Dravet syndrome treatment. Conversely, considerable parental distress was evident from diagnosis.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Long-term Effect of Cenobamate in a Cohort of Therapy Refractory Adult Patients with Different Types of Epilepsies (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1344;
The comedication was lamotrigine (49), valproate (41), clobazam (35), brivaracetam/levetiracetam (37), lacosamide (15), oxcarbazepine (15), perampanel (7), zonisamide (5), stiripentol (5), topiramate (4), phenobarbital (2), rufinamide (1), felbamate (1), carbamazepine (1). Overall, adjunct CNB has been found to be generally safe and effective for treatment-resistant seizures in adult pts, a few therapy-resistant pts got seizure free and the retention rate, a mixture of effect and side effects was 91.4% after 6 months.
- The Gain of Function SCN1A Disorder Spectrum: Novel Epilepsy Phenotypes and Therapeutic Implications (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1288;
Our study expands the spectrum of gain of function SCN1A-related epilepsy phenotypes, defines key clinical features, provides novel insights into the underlying disease mechanisms between SCN1A-related epilepsy and FHM3, and identifies sodium channel blockers as potentially efficacious therapies. Gain-of-function disease should be considered in early onset epilepsies with a pathogenic SCN1A variant and non-Dravet syndrome phenotype.
- Fycompa (perampanel) / Eisai, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Practice Trends in Women with Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1220;
Based on available data, several organizations including the AAN (American Academy of Neurology) and the AES (American Epilepsy Society) recommend avoidance of valproate use in women of child bearing age group due to substantial risk of major congenital malformations and adverse neuro-cognitive outcomes and recommend use of folic acid supplementation. However, our study finds that there is a practice gap between recommendations and clinician practice trends illustrating the need for more clinician education and need for involvement of epileptologists in the care of these patients to ensure best outcomes.
- Fycompa (perampanel) / Eisai
A Mirroring Clinical Practice Study of Perampanel in Adults and Adolescents (AMPA): Effect of Concomitant Enzyme-inducing Anti-seizure Medication (EIASM) During Adjunctive Perampanel Treatment (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1153;
P
Consistent with previous reports, these data suggest that adjunctive perampanel is efficacious and well tolerated in patients with insufficiently controlled FOS, with/without FBTCS, regardless of EIASM use. Patients receiving perampanel in combination with an EIASM may require a higher perampanel dose to achieve similar efficacy as with non-EIASMs, likely due to an increased exposure to perampanel among patients who receive non-EIASMs.
- Outcome of Pregnancies Following Maternal Exposure to Antiepileptic Drugs: Experience of a Single Tertiary Referral Center in Lebanon (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1088;
Our study is the first to report pregnancy outcome in women with epilepsy in Lebanon and to report the initial data of the Lebanese registry affiliated to the EURAP. Drugs prescribed and dosages used did not induce any birth defects and overall outcome was favorable even though most women struggled to have access to medical care or have drug levels checked because of the economical and healthcare collapse of the country.
- PRAX-562 / Praxis Precision Medicines
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-562 in Healthy Volunteers (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1084;
PRAX-562 exposure resulted in concentrations that exceeded the EC50 in the mouse maximal electroshock seizure (MES) model by 13-fold (based on Day 28 mean concentration), and was unaltered with OXC coadministration. PRAX-562 did not appear to alter the PK of OXC or its primary metabolite.
- clonazepam / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
The Role of High Dose Maternal Folic Acid Supplementation on the Association of Antiseizure Medication Use in Pregnancy with Standardized Test Scores of Danish School-aged Children (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1046;
PRAX-562 did not appear to alter the PK of OXC or its primary metabolite. In this nationwide study of Danish school-aged children, we found no evidence that maternal use of high dose folic acid supplements in pregnancy reduces the negative influence of prenatal valproate exposure on performance in standardized language and mathematics tests or modifies the association with other ASMs.
- Comparison of Antiseizure Medication Concentrations Measured Within and Outside a Central Laboratory (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1029;
Paired t-test was used to compare the concentration results between laboratories using R version 4.0.3. A p-value < 0.05 was considered statistically significant.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
The Pharmacokinetics of Cenobamate When Used as Monotherapy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1009;
The following antiseizure medications (ASMs) were tested as covariates for statistically significant effects on the apparent clearance (CL/F) of cenobamate based on their use in the clinical studies of patients with focal seizures: carbamazepine, clobazam, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and valproate. Based on these findings, cenobamate monotherapy should result in plasma exposures comparable to those that have been demonstrated to be safe and effective when used as adjunctive therapy for the treatment of focal seizures.
- VS-505 / Vidasym
Meta-analysis of Major Congenital Anomaly Outcomes Following Prenatal Exposure to Monotherapy Antiseizure Medications. (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1004;
Overall pooled data demonstrated that LTG and LEV exposure were associated with comparable MCA risks and tended to have a lower risk than CBZ and TPM exposures. Data were more limited in comparison to OXC exposure.
- levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Real-world Outcomes in Patients on Concomitant Levetiracetam at Brivaracetam Initiation: Post Hoc Analysis by Levetiracetam Discontinuation Status () - Nov 29, 2022 - Abstract #AES2022AES_921;
The remaining 50% of patients who continued on a stable dose of LEV had a lower BRV retention than patients who discontinued LEV. In patients remaining on BRV for ≥12 months, the proportion of seizure-free patients was similar irrespective of LEV discontinuation status.